Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies is attractive because clonoSEQ is gaining stronger clinical endorsement, with NCCN language in multiple myeloma expanding testing timepoints and reinforcing its role across ALL, MM, CLL, MCL, and LBCL, while the FDA-cleared assay remains the only named MRD test in the updated guidance. Fundamental momentum is also visible in the numbers: Q2'26 revenue rose 22% Y/Y to $72M, core MRD revenue grew 33% Y/Y to $66M, MRD volumes increased 43% Y/Y to 36.1k, and adjusted EBITDA for MRD reached $9M with 71% sequencing gross margins. The outlook is further supported by rising ASPs to $1,382/test, guidance for 38%-40% MRD volume growth in 2026, $357M of cash, and a planned separation of the profitable MRD business from the non-core immune medicine segment, which should improve valuation transparency and highlight the core franchise’s growth profile.

Adaptive Biotechnologies is viewed negatively because its valuation depends on a premium multiple despite the company’s continued losses, creating a risk that execution must improve materially before fundamentals can justify investor expectations. The outlook is further pressured by adoption uncertainty, reimbursement and clinical guideline hurdles, and the possibility that new competition slows growth in clonoSEQ and broader MRD testing, even though the business relies on the Minimal Residual Disease segment for most revenue. More broadly, the excerpts highlight sectorwide headwinds such as delayed R&D budgets, weaker hospital purchasing, and macroeconomic volatility, all of which could impede the path to profitability.